Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Net Cash Flow (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Net Cash Flow data on record, last reported at -$4.2 million in Q3 2025.

  • For Q3 2025, Net Cash Flow fell 117.34% year-over-year to -$4.2 million; the TTM value through Sep 2025 reached -$13.8 million, down 150.22%, while the annual FY2024 figure was -$3.9 million, 158.75% down from the prior year.
  • Net Cash Flow reached -$4.2 million in Q3 2025 per PLX's latest filing, down from -$1.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $28.3 million in Q4 2021 and bottomed at -$27.8 million in Q3 2023.
  • Average Net Cash Flow over 5 years is $701842.1, with a median of -$294000.0 recorded in 2025.
  • Peak YoY movement for Net Cash Flow: soared 502.96% in 2021, then plummeted 1483.83% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at $28.3 million in 2021, then tumbled by 77.33% to $6.4 million in 2022, then tumbled by 49.31% to $3.3 million in 2023, then tumbled by 336.8% to -$7.7 million in 2024, then skyrocketed by 45.01% to -$4.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$4.2 million in Q3 2025, -$1.6 million in Q2 2025, and -$294000.0 in Q1 2025.